

## Looking Beyond 95%: A New Data-Driven Framework to Assess Regulatory Approval Risk

2024 SDP Conference Presenters: Lan Ding, Eric Johnson



# What this Is and Is NOT?

### IS:

- A real case
- About Decision Quality Deployment
- About Innovation and Change Management

## **IS NOT:**

 Academia talk on how to evaluate Probability of Regulatory Success
 (neither Eric nor Lan is regulatory expert)




#### **Problem Statements:**

- 95% PRS (industry benchmark) was widely used and lack of consistent approach for adjustments.
- People internalize risks differently. Challenging discussions were observed at governance as lack of agreement on how to quantify regulatory risks.

#### Mission:

 A cross- functional working force was formed to develop a robust framework and process to capture the key regulatory risks and guide teams to systematically evaluate and quantify regulatory probability of success.

# Key Steps Leading Towards the New Framework?



## **Output: PRS Assessment Framework**

**Regulatory Factor 1: Regulatory Considerations**: 'Do we have clear regulatory path\*? Does the programme follow the regulatory path?'. Any opportunity to shape the regulatory environment or guidelines? Any known upcoming policy change?

\* Regulatory path include regulatory guidelines, precedents and/or obtained health authority feedbacks.

**Regulatory Factor 2: Unmet Needs:** 'Is there clear unmet needs? Will high unmet needs increase regulatory flexibility?'

**Regulatory Factor 3: Clinical Data Package:** 'any potential perceived gaps from HAs?'

**Regulatory Factor 4: Pre-Clinical & CMC Data Package:** *'any potential perceived gaps from HAs?'* 

Within each regulatory factor, we provided a list of risks for consideration and developed Red, Amber, Green statements. Details are not included due to business confidentiality.

### GSK

## Examples of Regulatory Factor Scenarios and Associated PRS Based on Elicitation Results

Regulatory Factor Scenarios*	Regulatory Considerations	Unmet Need	Clinical Data Package	Pre-Clinical & CMC Data Package	Estimated PRS
1. No perceived regulatory risks likely to impact approvability	Green	Green	Green	Green	95%
2. Development plan broadly aligned with regulatory path, but some outstanding issues	Amber	Green	Green	Green	84%
<ol> <li>As in 2. but also high unmet need</li> </ol>	Amber	Hyper- Green	Green	Green	89%
4. Development plan, trial design etc. is not aligned with existing regulatory path and there is important misalignment and/or disagreement	Red	Green	Green	Green	61%
5. Clinical, pre-clinical and CMC data packages are likely to have some small gaps.	Green	Green	Amber	Amber	<b>70%</b>

## **Bringing Framework to Life - A Web-based User-friendly Tool**

GSK PRS Evaluation Tool

Calculator Description

#### **Risk Profile Selection**

#### Project ID

001	Project ID: 001		
Risk Factor 1: Regulatory	Risk Factor	Risk Category	Description
Considerations          Amber       •         Risk Factor 2: Unmet Need       •	Regulatory Considerations	Amber	Clear regulatory path, and the development plan, trial designs and/or key endpoints etc are broadly aligned with the existing regulatory path, but there are some outstanding issues/reservations/risks
Green	Unmet Need	Green	Neutral scenario (e.g. no regulatory designation or significant benefit vs well established SoC) without adjustment to PRS
Green •	Clinical Data Package	Green	The planned Clinical data package is deemed to be sufficient for filling
Risk Factor 4: Pre-Clinical & CMC Data Package			The planned pre-Clinical & CMC data package is deemed to be sufficient for filling
Green	PRS Estimate84%95% Confidence Interval82%, 86%		Tool provides team with recommended PRS for their selected regulatory profile

# Potential Risks & Mitigation Strategies

Risks	Prob / Impact	Mitigation strategy
Systematically driving portfolio level PRS away from 95%	M/H	<ul> <li>Communicate the tool provides <u>directional</u> reference</li> <li>Tool is intended to support decision not to direct it (Mindset change)</li> </ul>
Team miscategorising the risk	M/M	<ul> <li>Training</li> <li>Facilitated discussion and assessment</li> </ul>
Team commonly deviating from the PRS number recommended by tool	M/M	<ul> <li>Boost confidence (tool was built based on elicitation with over 30+ experienced experts across Therapeutic Areas)</li> <li>Continuously track, periodically review and appraise</li> </ul>

# A Few Thoughts on...

- Innovation
- Push vs. Pull
- Stakeholder Management
- Matrix Team: Forming & Performing
- Disagreements